US 11,959,116 B2
Method for producing nicotinamide mononucleotide
Takeshi Matsuoka, Tokyo (JP); Tatsuya Hirata, Tokyo (JP); and Masaru Yamakoshi, Tokyo (JP)
Assigned to ASAHI KASEI PHARMA CORPORATION, Tokyo (JP)
Filed by Asahi Kasei Pharma Corporation, Tokyo (JP)
Filed on Oct. 26, 2022, as Appl. No. 17/974,381.
Claims priority of application No. 2021-175812 (JP), filed on Oct. 27, 2021.
Prior Publication US 2023/0125968 A1, Apr. 27, 2023
Int. Cl. C12P 19/30 (2006.01); C12N 9/10 (2006.01)
CPC C12P 19/30 (2013.01) [C12N 9/1077 (2013.01); C12Y 204/02008 (2013.01)] 11 Claims
 
1. A method for making nicotinamide mononucleotide (NMN), which method comprises at least the following steps 1) and 2):
1) Reacting a hypoxanthine phosphoribosyltransferase (HPT, EC 2.4.2.8) in a reaction mixture with a nucleoside monophosphate at a concentration of 0.01-500 mM and pyrophosphate at a concentration of 0.001-100 mM to produce phosphoribosyl diphosphate (PRPP); and
2) Reacting said HPT in the reaction mixture with said PRPP and nicotinamide to produce nicotinamide mononucleotide (NMN) at a concentration of 0.01-500 mM;
wherein said nucleoside monophosphate is at least one member selected from the group consisting of adenosine monophosphate (AMP), 5′-guanylic acid (GMP), inosinic acid (IMP) and xanthosine monophosphate (XMP), said HPT is present in said reaction mixture in an amount of 0.01 U-1000 kU/L and said HPT is present in an amount of at least 90% of any enzymes present in said reaction mixture, wherein said at least 90% indicates enzyme protein weight or a unit of activity for the enzyme.